MX2022005985A - Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. - Google Patents
Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.Info
- Publication number
- MX2022005985A MX2022005985A MX2022005985A MX2022005985A MX2022005985A MX 2022005985 A MX2022005985 A MX 2022005985A MX 2022005985 A MX2022005985 A MX 2022005985A MX 2022005985 A MX2022005985 A MX 2022005985A MX 2022005985 A MX2022005985 A MX 2022005985A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- medical use
- heteroaryl derivative
- pyrazole
- derivative
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describe un derivado de pirazolo-heteroarilo, un método de preparación del mismo y uso médico del mismo. En particular, la presente invención se refiere a un derivado de pirazolo-heteroarilo como se muestra en la fórmula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el derivado y su uso como agente terapéutico, particularmente como inhibidor de la quinasa ATR y en la preparación de fármacos para el tratamiento y/o prevención de enfermedades hiperproliferativas. La definición de cada grupo en la fórmula general (I) es idéntica a la de la memoria descriptiva. (ver Fórmula).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911147956 | 2019-11-21 | ||
| CN202010837381 | 2020-08-19 | ||
| PCT/CN2020/130326 WO2021098811A1 (zh) | 2019-11-21 | 2020-11-20 | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005985A true MX2022005985A (es) | 2022-06-17 |
Family
ID=75981069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005985A MX2022005985A (es) | 2019-11-21 | 2020-11-20 | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230018728A1 (es) |
| EP (1) | EP4063363A4 (es) |
| JP (1) | JP2023502458A (es) |
| KR (1) | KR20220103987A (es) |
| CN (5) | CN120004872A (es) |
| AU (1) | AU2020386587A1 (es) |
| BR (1) | BR112022008000A2 (es) |
| CA (1) | CA3159376A1 (es) |
| MX (1) | MX2022005985A (es) |
| TW (1) | TW202128690A (es) |
| WO (1) | WO2021098811A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022028598A1 (en) * | 2020-08-07 | 2022-02-10 | Shanghai Antengene Corporation Limited | Atr inhibitors and uses thereof |
| EP4267581A4 (en) * | 2020-12-25 | 2025-01-01 | Impact Therapeutics (Shanghai), Inc | SUBSTITUTED IMIDAZO[1,5-B PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND THEIR USE |
| BR112023024037A2 (pt) * | 2021-05-21 | 2024-02-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Sal farmaceuticamente aceitável de derivado de pirazoloheteroarila, formas cristalinas, composição farmacêutica, usos dos mesmos e métodos para preparar as referidas formas cristalinas e composição farmacêutica |
| CN116262749A (zh) * | 2021-12-15 | 2023-06-16 | 上海翊石医药科技有限公司 | 一类芳杂环取代的化合物及其制备方法和用途 |
| CN120187722A (zh) * | 2022-11-21 | 2025-06-20 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110053923A1 (en) * | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| WO2012078777A1 (en) * | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| SG11201507203RA (en) * | 2013-03-12 | 2015-10-29 | Vertex Pharma | Dna-pk inhibitors |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| EP3402795B1 (en) * | 2016-01-14 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| WO2018153970A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| WO2020049017A1 (en) * | 2018-09-07 | 2020-03-12 | Merck Patent Gmbh | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives |
| US11111247B2 (en) * | 2018-09-25 | 2021-09-07 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
-
2020
- 2020-11-20 JP JP2022529505A patent/JP2023502458A/ja active Pending
- 2020-11-20 WO PCT/CN2020/130326 patent/WO2021098811A1/zh unknown
- 2020-11-20 CN CN202510104960.0A patent/CN120004872A/zh active Pending
- 2020-11-20 MX MX2022005985A patent/MX2022005985A/es unknown
- 2020-11-20 TW TW109140787A patent/TW202128690A/zh unknown
- 2020-11-20 KR KR1020227019663A patent/KR20220103987A/ko active Pending
- 2020-11-20 US US17/778,632 patent/US20230018728A1/en active Pending
- 2020-11-20 EP EP20890856.6A patent/EP4063363A4/en active Pending
- 2020-11-20 CN CN202510105045.3A patent/CN120004886A/zh active Pending
- 2020-11-20 CN CN202510105174.2A patent/CN120004888A/zh active Pending
- 2020-11-20 AU AU2020386587A patent/AU2020386587A1/en active Pending
- 2020-11-20 CA CA3159376A patent/CA3159376A1/en active Pending
- 2020-11-20 BR BR112022008000A patent/BR112022008000A2/pt unknown
- 2020-11-20 CN CN202080066108.4A patent/CN114423760B/zh active Active
- 2020-11-20 CN CN202510105110.2A patent/CN120004887A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021098811A1 (zh) | 2021-05-27 |
| EP4063363A4 (en) | 2023-11-29 |
| CN120004887A (zh) | 2025-05-16 |
| CA3159376A1 (en) | 2021-05-27 |
| CN120004888A (zh) | 2025-05-16 |
| US20230018728A1 (en) | 2023-01-19 |
| CN114423760B (zh) | 2024-12-27 |
| CN114423760A (zh) | 2022-04-29 |
| KR20220103987A (ko) | 2022-07-25 |
| CN120004886A (zh) | 2025-05-16 |
| TW202128690A (zh) | 2021-08-01 |
| CN120004872A (zh) | 2025-05-16 |
| EP4063363A1 (en) | 2022-09-28 |
| AU2020386587A1 (en) | 2022-06-02 |
| JP2023502458A (ja) | 2023-01-24 |
| BR112022008000A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| MX2019001481A (es) | Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo. | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2019011606A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
| ECSP12011834A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos. | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| BR112018011969A2 (pt) | compostos heteroaromáticos como inibidores de btk | |
| MX2019013893A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112019024322A2 (pt) | Compostos e composições terapêuticos e métodos de uso dos mesmos | |
| CL2019003572A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| MX390755B (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. |